View Profile

General information

Company profile	Ethris has created a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA (mRNA) and lipidoid nanoparticle (LNP) technology plattforms to discover, design and develop innovative therapies and vaccines. As an mRNA pioneer for more than a decade, our technologies enable the delivery of highly potent mRNA-based drug products directly to the upper and lower respiratory tract and via intra-muscular injection. Ethris’ differentiated plattforms produce drug candidates with superior thermostability, resistance to mechanical manipulation and are nebulizable at high throughput, without change in biophysical properties or potency. We are developing our first-in-class, virus-agnostic, anti-viral treatment for COVID-19, influenza, and viral asthma exacerbations while advancing our pipeline of immunomodulation and mRNA-based protein replacement therapies and vaccines with the ul􀆟mate goal of improving patients’ lives.
Products & Services	Ethris pipeline focuses on respiratory rare diseases: • Primary Ciliary Dyskinesia (ETH42) CTA Q4/2023 • Pulmonary Alveolar Proteinosis (ETH45) • Viral asthma exacerbations (ETH47) CTA Q2/2023 • Vacccines (intramuscular and nasal) Ethris is interested in collaborations for licensing of its technology platform, co-development of new mRNA vaccines and therapeutics, and licensing partners for future commercialization of existing pipeline programs. Ethris is also interested in strategic and financial investors for further development of the company’s pipeline
References and export activities	Collaborations with high profile industry and academic partners: • Cepi grant in collaboration with DioSynVax • Strategic investment by Cipla • Partner in various national research consortia funded by the German and Bavarian government • Partner in various international research consortia funded by the European Union
Target group	– Pharma & Biotech companies interested in licensing mRNA technology – Partners for development of clinical assets in the mRNA space – CDMOs interested in mRNA manufacturing technology – Pharma, Biotech and academic partners for leveraging Ethris delivery platform in other areas e.g., gene therapy – Pharma & Biotech investors
Competitive advantages	– Fully proprietary technology for mRNA and LNPs – Stabilizing formulation – Proprietary manfucaturing process – Nebulization of mRNA without LNP aggregation
Ideal Business Partners	Pharma and Biotech companies looking to enter the mRNA space for therapeutics and vaccines